Shibuya-ku, Tokyo, Japan, Japan, Mar 08, 2021, 01:12 /Comserve / -- Key Players: Gilead Sciences Inc., Abbvie Inc., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline plc, Vertex Pharmaceuticals Inc., Novartis AG, Hoffmann-La Roche Ltd., and other predominate & niche players.
Overview: Hepatitis is a medical condition where the liver is predominantly affected, which can also affect the digestive system and brain. There are three major types of hepatitis condition – HAV, HBV, and HCV. HCV is a major public health problem that attacks the liver and leads to inflammation. Certain drugs, toxins, heavy alcohol use, bacterial and viral infections can cause hepatitis infection. Hepatitis C infection can bring both acute and chronic hepatitis disease. Approximately, 80% of the patients get chronically infected with Hepatitis C disease. Hepatitis C Virus (HCV) spreads through the blood of an infected individual by the use of shared needles or supplies used to infuse drugs. Vaccines are available only for Hepatitis A and Hepatitis B viruses. Research into the development of a vaccine for Hepatitis C is under way.
Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-107197
"The Final Report will cover the impact analysis of COVID-19 on this industry (Global And Regional Market)."
Key Players: Gilead Sciences Inc., Abbvie Inc., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline plc, Vertex Pharmaceuticals Inc., Novartis AG, Hoffmann-La Roche Ltd., and other predominate & niche players.
Competitive Analysis: At present, the HCV drugs are dominating the Global Hepatitis Drugs market – but, a lot of new players are focusing on developing HBV drug molecules to gain future business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of hepatitis molecules and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.
Table of Content
1 Industry Outlook 9
1.1 Industry Overview 9
1.2 Industry Trends 10
1.3 Pest Analysis 11
2 Report Outline 12
2.1 Report Scope 12
2.2 Report Summary 12
2.3 Research Methodology 13
2.4 Report Assumptions 13
3 Market Snapshot 14
3.1 Total Addressable Market (TAM) 14
3.2 Disease Overview 15
3.2.1 Hepatitis A 15
3.2.1.1 Epidemiology 15
3.2.1.2 Therapy 15
3.2.2 Hepatitis B 15
3.2.2.1 Epidemiology 15
3.2.2.2 Therapy 16
3.2.3 Hepatitis C 16
3.2.3.1 Epidemiology 16
3.2.3.2 Therapy 17
3.2.4 Hepatitis D 18
3.2.5 Hepatitis E 19
3.3 Disease Transmission 19
3.4 Related Markets 20
4 Market Outlook 21
4.1 Overview 21
4.2 Regulatory Bodies & Standards 21
4.3 Porter 5 (Five) Forces 22
5 Market Characteristics 23
5.1 Evolution 23
5.2 ROADMAP 24
5.3 Market Dynamics 25
5.3.1 Drivers 25
5.3.1.1 Increasing Demand of Hepatitis Drugs 25
5.3.1.2 Focus on Advanced DAAs 25
5.3.1.3 Introduction of IFN-free Therapies 26
5.3.1.4 Growth of Injection Drug Users 26
5.3.2 Restraints 27
5.3.2.1 Long Approval Process and Stringent Regulations 27
5.3.2.2 Side Effects of Hepatitis Drugs 27
5.3.2.3 Increase in the Number of Generic Drugs 27
5.3.2.4 Increasing Market Competition 27
5.3.3 Opportunities 28
5.3.3.1 Significant Increase in Mergers and Acquisitions 28
5.3.3.2 Emergence of Combination Drugs 28
5.3.3.3 Preventive Healthcare 28
5.3.3.4 Focus of Companies on Emerging Market 29
5.3.4 DRO – Impact Analysis 29
Request to Fill The Form To get Sample Copy of This Report: https://www.sdki.jp/sample-request-107197
"The Final Report will cover the impact analysis of COVID-19 on this industry (Global And Regional Market)."
Benefits: The report provides complete details about the usage and adoption rate of hepatitis drugs in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives towards the hepatitis drugs adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.
For more information, please contact:
Lauren BrownShibuya Data Count
Email: sales@sdki.jp
Tel: + 81 50 50509159
Related Links
https://www.sdki.us/